Top Drug Discovery and Development Companies in Latam
Nominate a Company
Usually, the qualified subscribers of our magazine nominate companies with whom they have collaborated and experienced exceptional results to be in this list. Did a company you recently worked with give you stellar results and ROI? Did it turn out to be one you would wholeheartedly recommend to peers? Or do you know of such an outstanding company through your network? Please fill in the details below and nominate them to be featured here.
Top Drug Discovery and Development Companies in Latam
Drug Discovery and Development News
Translating Microbiome Findings into Clinical Programs Remains a Major Execution Hurdle
Monday, July 06, 2026
Many discussions about microbiome science focus on discovery. Far less attention is given to the practical work required after a promising finding emerges. Across Latin America's precision medicine landscape, that implementation stage is becoming a critical area of focus. Identifying microbiome patterns is only the beginning of a much longer process. Development teams must determine whether those observations can be reproduced, whether they remain consistent across patient populations and whether they support meaningful clinical decisions. Each step introduces additional complexity. The transition from research environments into development programs often exposes g
Latin America's Microbiome Research Push Raises New Questions for Drug Development Programs
Monday, July 06, 2026
Interest in microbiome science is expanding across Latin America, but the discussion is moving beyond research activity alone. Attention is increasingly focused on how microbiome data can be translated into precision medicine programs that support drug development, patient stratification and treatment design. The challenge is not simply generating more biological information. Researchers and development teams are trying to determine which microbiome signals are clinically meaningful and how those findings can be integrated into existing development pathways. That distinction is becoming important as precision medicine programs look for factors that may help explain differences i
Precision Medicine Buyers Look for Stronger Evidence from Microbiome Service Providers
Monday, July 06, 2026
Procurement decisions around precision medicine development are becoming more complex as microbiome research gains visibility. Buyers are no longer evaluating providers solely on scientific expertise. They are increasingly examining whether microbiome-related findings can support practical development objectives. That shift reflects a broader change in how development programs are assessed. Research sponsors face growing pressure to justify investments in specialized biological analysis. Interest in microbiome science remains high, but purchasing decisions are becoming more closely tied to evidence quality, study execution and translational relevance. Microbiome-focuse
Advancing Precision in Gynaecology and Neuro-Psychiatry Therapeutics
Wednesday, May 13, 2026
Therapeutic development in gynaecology and neuro-psychiatry presents a distinct challenge for decision-makers. Clinical variability remains high, particularly in neuro-psychiatric conditions where prescribing often relies on iterative adjustment rather than predictable response. In gynaecology, conventional treatment pathways still rely heavily on standardised interventions that may not account for individual microbiological or metabolic differences. Executives responsible for sourcing development partners must therefore look beyond scale or speed and focus on scientific depth, clinical validation discipline and ability to translate research into sustained physician confidence.
Shaping Healthcare through Microbiome Science in Latin America
Monday, May 04, 2026
Microbiome science has moved from an exploratory research field into a meaningful component of modern biomedical innovation. Across Latin America, the intersection of microbiome research and precision medicine development is beginning to reshape how disease risk, treatment response, and therapeutic design are understood. The region presents a distinctive biological and demographic context, characterized by diverse genetic backgrounds, varied dietary traditions, and unique environmental exposures. These factors create a rich foundation for microbiome research that can inform more individualized approaches to healthcare. As laboratories, research institutions, and clinical network
Evaluating Pharmaceutical Outsourcing Medical Advertising Services
Wednesday, April 29, 2026
Pharmaceutical companies expanding across diverse markets increasingly rely on outsourced medical advertising and field engagement partners to strengthen physician relationships while maintaining strict regulatory discipline. The challenge extends beyond promotional reach. Executives responsible for external medical engagement must ensure that scientific messaging remains compliant, locally relevant and capable of producing measurable changes in physician understanding and prescribing behavior. Markets across Latin America illustrate the complexity particularly well. Fragmented healthcare networks, varied institutional access barriers and differences in digital readiness among clinicians
